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Background. The effect of early initiation of antiretroviral therapy (ART; ie, at CD4+ T-cell counts >350 cells/mm3)
on sexual behaviors and human immunodeﬁciency virus type 1 (HIV) transmission risk has not been documented in
populations other than HIV-serodiscordant couples in stable relationships.
Methods. On the basis of data from a behavioral study nested in a randomized, controlled trial (Temprano-
ANRS12136) of early ART, we compared proportions of risky sex (ie, unprotected sex with a partner of negative/
unknown HIV status) reported 12 months after inclusion between participants randomly assigned to initiate ART imme-
diately (hereafter, “early ART”) or according to ongoing World Health Organization criteria. Group-speciﬁc HIV trans-
mission rates were estimated on the basis of sexual behaviors and viral load–speciﬁc per-act HIV transmission
probabilities. The ratio of transmission rates was computed to estimate the protective effect of early ART.
Results. Among 957 participants (baseline median CD4+ T-cell count, 478 cells/mm3), 46.0% reported sexual activi-
ty in the past month; of these 46.0%, sexual activity for 41.5% involved noncohabiting partners. The proportion of sub-
jects who engaged in risky sex was 10.0% in the early ART group, compared with 12.8% in the standard ART group
(P = .17). After accounting for sexual behaviors and viral load, we estimated that the protective effect of early ART was
90% (95% conﬁdence interval, 81%–95%).
Conclusion. Twelve months after inclusion, patients in the early and standard ART groups reported similar sexual
behaviors. Early ART decreased the estimated risk of HIV transmission by 90%, suggesting a major prevention beneﬁt
among seronegative sex partners in stable or casual relationships with seropositive individuals.
Keywords. HIV prevention; antiretroviral treatment; sexual behaviors; HIV-1 sexual transmission; treatment as
prevention; epidemiology; sub-Saharan Africa.
By controlling viral replication, antiretroviral therapy
(ART) reduces the infectivity of human immunodeﬁ-
ciency virus type 1 (HIV)–positive patients, with some ev-
idence that patients with an undetectable viral load
have a negligible HIV transmission risk [1, 2]. In 2011,
the HPTN052 trial demonstrated that initiating ART at
a CD4+ T-cell count of 350–550 cells/mm3, which is
greater than the CD4+ T-cell count of <350 cells/mm3
recommended in 2010 by World Health Organization
(WHO) guidelines, had a 96% preventive effect against
HIV transmission among HIV-serodiscordant couples
in a stable relationship [3]. This evidence strength-
ened the treatment-as-prevention concept, under which
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providing ART to all HIV-infected patients, regardless of their
CD4+ T-cell count, might decrease HIV transmission among
the general population to such an extent that it would curtail
the HIV pandemic [4, 5]. Results of randomized, controlled
trials of treatment as prevention are not expected for several
years [6]. Meanwhile, there are still questions regarding factors
that might impact the effect of early ART in the general popula-
tion and make this effect different from that observed in the
very speciﬁc group of stable serodiscordant couples.
Among these factors, the inﬂuence of early ART on risky
sexual behaviors is one of major concern. In the ﬁrst years of
the highly active ART era, increased risky sexual behaviors as-
sociated with ART were reported among high-risk groups [7,
8]. Risk compensation related to decrease in perception of HIV
transmission risk and severity of HIV infection may potentially
offset the protective effect of early ART [9, 10]. Nevertheless, a
recent review of observational studies conducted in developing
countries instead suggested a decrease in risky sexual behaviors
after ART initiation [11]. However, such studies may be subject
to confounding. In addition, only a few were prospective [12],
and all were conducted in the context of standard ART initia-
tion [11, 13]. Starting ART earlier, while patients are healthy,
may inﬂuence sexual behaviors differently. Updating results
about this issue, especially in the current context of early ART
initiation, is thus needed [14].
Evidence obtained so far has resulted in WHO recommenda-
tions of early ART for prevention speciﬁcally for the population
of serodiscordant couples [15]. Nevertheless, according to a
recent estimation, only less than a third of new HIV transmis-
sions in sub-Saharan Africa occur among these couples [16].
This suggests that programs solely targeting stable serodiscord-
ant couples may lack the ability to prevent the majority of new
infections. Estimating the preventive effect of early ART
beyond the population of stable serodiscordant couples is thus
of great interest for scaling up effective prevention strategies.
Relying on data from the ongoing Temprano-ANRS12136
randomized, controlled trial, we aimed to measure the impact
of early ART initiation on sexual behaviors and to estimate its
protective effect among a West African adult population re-
porting diverse heterosexual partnership statuses (ie, serodis-
cordant, seroconcordant, stable, or casual).
MATERIAL ANDMETHODS
Temprano-ANRS12136 Trial
Temprano is a multicenter, randomized, open-label superiority
trial to assess the beneﬁts and risks of initiating ART earlier
than currently recommended by the WHO, concomitantly or
not with 6-month isoniazid prophylaxis for tuberculosis. The
trial was launched in March 2008 in Abidjan, Côte d’Ivoire,
and is still ongoing. The trial protocol was approved by the
ethics committee of the Ministry of Health of Côte d’Ivoire and
by the institutional review board of the French National
Agency for Research on AIDS and Viral Hepatitis (ANRS;
Paris, France). The study has been registered on Clinicaltrials.
gov (clinical trials identiﬁer NCT00495651).
Between March 2008 and July 2012, patients attending 9 care
centers in Abidjan were included in the trial whenever they
provided signed, informed consent; were aged >18 years;
had HIV-1 infection or HIV-1/HIV-2 dual infection; had
no ongoing active tuberculosis; had no ongoing pregnancy
and/or were not breast-feeding; and had a CD4+ T-cell count
<800 cells/mm3 and satisﬁed no criteria for starting ART, ac-
cording to the most recent WHO guidelines. Participants were
randomly assigned to one of 4 arms: 2 “standard ART” arms
(arms 1 and 2), in which ART was delayed until patients meet
ongoing WHO starting criteria [17, 18]; and 2 “early ART”
arms (arms 3 and 4), in which ART was initiated immediately
on inclusion. In arm 2 and arm 4, participants received 6-
month isoniazid prophylaxis for tuberculosis, starting at the 1-
month visit and stopping at the 7-month visit. Once included,
participants were asked to show up for trial scheduled visits
every 3 months. CD4+ T-cell count and plasma HIV-1 RNA
load (real-time polymerase chain reaction, TaqMan technology;
ABI Prism 7000, Applied Biosystems; lower limit of detection,
300 copies/mL) were measured every 6 months. Each partici-
pant was to be followed during 30 months. The main outcome
of the trial is the occurrence of a new episode of severe morbidi-
ty and any event leading to death.
Sociobehavioral Study
The present sociobehavioral study was nested in the Temprano
trial. All participants included in Temprano between 1 January
2009 and 1 September 2011 were eligible for the study. A stan-
dardized questionnaire was used to collect information on
sexual behaviors. Participants completed this questionnaire
face to face at the 12-month visit.
Study Outcomes
Sexual behaviors of interest included sexual activity and multi-
ple partnerships in the past year, as well as characteristics of the
last episode of sexual intercourse, including date (occurrence in
the past month or the past year), type of partnership (cohabit-
ing or not), and partner’s HIV status (unknown, negative, or
positive).
Risky sex at the last episode of sexual intercourse in the past
month was deﬁned as an episode of unprotected intercourse
with a partner whose HIV status was negative or unknown.
Partner’s exposure to HIV infection was deﬁned as risky sex
at the last episode of sexual intercourse in the past month plus
a viral load of >300 copies at the time of the intercourse, i.e.
measured within a period ranging from 30 days before to
7 days after the date of completion of the sociobehavioral
questionnaire.
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For each sexually active participant, the risk of HIV trans-
mission during the last episode of intercourse in the past
month was calculated on the basis of the reported partner’s
HIV status, condom use, and viral load measured at the time of
the intercourse. Per-coital-act viral load–speciﬁc probabilities
of transmission were derived from a seroconversion study of
HIV-discordant couples in eastern and southern Africa [19],
using the following formula:
p ¼ 1 eeð7:257þ1:070ðLogðVLÞ4Þ0:025ðage35ÞÞ;
where p is the per-coital probability of HIV transmission
( J. P. Hughes, personal communication).
Patients with an undetectable viral load were assigned a null
transmission risk [2]. We attributed a 78% transmission risk re-
duction if condom use was reported, and for female participants
we considered each last male sex partner as circumcised (96% of
men actually are in Côte d’Ivoire [20]) and thus used a 53%
transmission risk reduction [19]. Partners with an unknown
HIV status were considered as HIV uninfected. For a partner re-
ported as HIV positive, the transmission risk was set to 0.
We estimated HIV transmission rates at the last episode of
sexual intercourse in the past month for both ART strategies by
computing mean values of individual transmission risks, ex-
pressed as the number of transmissions per 10 000 sexually
active individuals. To estimate transmission rates overall rather
than among sexually active persons only, we computed an addi-
tional estimate that included participants who were sexually in-
active in the past month, attributing to them a null individual
transmission risk.
Statistical Analysis
Participants included in the Temprano trial between 1 January
2009 and 1 September 2011 were included in this analysis pro-
vided they completed the sociobehavioral questionnaire within
9–15 months after enrollment in the Temprano trial. Analyses
were conducted on the basis of intention to treat. Sexual behav-
iors of interest were compared between early ART and standard
ART strategies, using χ2 tests. The protective effect of the early
ART strategy on the HIV transmission risk was based on the
ratio of transmission rates.
To assess the robustness of our estimates, we conducted a
range of sensitivity analyses, considering (1) only participants
with a baseline CD4+ T-cell count of > 350 cells/mm3, (2) only
those engaged in a cohabiting serodiscordant relationship, (3) a
nonnull transmission probability for those having a viral load
of < 300 copies/mm3 [21], (4) an alternative data set for viral
load–speciﬁc transmissions probabilities [22], (5) an HIV-
positivity probability of 0.4 for a sex partner with an unknown
serostatus, (6) all participants as having had an HIV-negative
partner during the last episode of unprotected sexual inter-
course.
All analyses were conducted using SAS, version 9.3 (SAS In-
stitute, Cary, NC). We computed 95% conﬁdence intervals
(CIs) for expected transmission rates and the protective effect
of early ART, using bootstrapping (10 000 resampling).
RESULTS
Study Population
Among the 1172 participants included in the Temprano trial
between 1 January 2009 and 1 September 2011, 957 (81.7%)
were included in the analyses (standard ART group, 467 pa-
tients; early ART group, 490 patients). Participants in the early
and standard ART groups attended a similar mean number of
trial medical visits between enrollment and 12 months (stan-
dard ART group, 5.9 visits; early ART group, 6.2 visits).
The remaining 215 patients (123 in the standard ART group
vs 92 in the early ART group; P = .03) were excluded for the fol-
lowing reasons: death within the ﬁrst 12 months (6 and 9, re-
spectively; P = .42), not showing up for the 12-month visit (17
and 38, respectively; P = .003); 12-month sociobehavioral ques-
tionnaire not or untimely completed (93 [of whom 59 had initi-
ated ART before the 12-month visit] and 30, respectively;
P = .02).
Participants included in the study did not differ from those
who were excluded with regard to sociodemographic character-
istics, except for education level (47.1% of patients included,
compared with 38.1% of those excluded, had at least a second-
ary level of education; P = .02).
Among the 957 participants, a large majority (80.4%) were
women. At baseline, the median age was 35 years, and 442 par-
ticipants (46.2%) were living in union. The median CD4+ T-
cell count was 478 cells/mm3. Neither baseline sociodemo-
graphic and clinical characteristics (Table 1) nor baseline viral
load distributions (P=.53, by the Wilcoxon rank sum test;
Figure 1A) signiﬁcantly differed between participants in the
early and standard ART groups.
At the 12-month visit, 70 patients (15.0%) in the standard
ART group had initiated ART (median duration between inclu-
sion and ART initiation, 9.5 months). Overall, viral load mea-
sured at 12-month was available for 427 patients (91.4%)
receiving standard ART and 468 (95.5%) receiving early ART.
As expected, because of the difference in ART coverage, the
percentage of patients with an undetectable viral load was sig-
niﬁcantly lower among those receiving standard ART, com-
pared with those receiving early ART (P < 10−3, by the
Wilcoxon rank sum test; Figure 1B).
Sexual Behaviors, Risky Sex, and Partner’s Exposure to HIV at
the 12-Month Visit
Sexual behaviors in the past 12 months are presented in
Table 2. No signiﬁcant difference was observed between pa-
tients receiving standard versus early ART in the proportions
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of sexual activity (71.7% in the standard ART group vs 69.8%
in the early ART group; P = .51) and multiple partnerships
(6.2% vs 9.0%, respectively; P = .11) in the past year. Among
sexually active participants, 41.2% in the standard ART group
and 41.8% in the early ART group reported they were not co-
habiting with their last sex partner (P = .87). Overall, the last
sex partner was reported to be HIV uninfected by 26.6% in the
standard ART group, compared with 22.8% in the early ART
group, and to have an unknown HIV-status by 43.9% and
47.7%, respectively (P = .47).
Characteristics of the last episode of intercourse in the past
month are presented in Table 3. Overall, 46.0% reported sexual
activity in the past month; of these 46.0%, sexual activity for
41.5% involved noncohabiting partners. Participants receiving
standard versus early ART did not signiﬁcantly differ as regard
to sexual activity in the past month and condom use. Risky sex
was reported by 12.8% of participants in the standard ART
group, compared with 10.0% in the early ART group (P = .54).
When taking into account the last available viral load, the pro-
portions of participants exposing their partner to HIV infection
were 10.7% in the standard ART group, compared with 2.4%,
in the early ART group (P < .001).
Estimated HIV-Transmission Rates at the 12-Month Visit
Figure 2A shows the estimated HIV transmission rates per
10 000 sexually active persons at the last episode of sexual inter-
course in the past month, based on risk behaviors and viral
load data, for both ART strategies. The estimated transmission
rate was 4.0 cases/10 000 (95% CI, 3.0–5.0) among those receiv-
ing standard ART and 0.5 cases/10 000 (95% CI, .2–.8) among
those receiving early ART. The corresponding estimated pro-
tective effect of early ART against HIV transmission was 89%
(95% CI, 79%–95%). When including all participants in the
computations (Figure 2B), the estimated transmission rate was
1.9 cases/10 000 (95% CI, 1.4–2.4) among those receiving stan-
dard ART and 0.2 cases/10 000 (95% CI, .1–.3) among those re-
ceiving early ART, representing a protective effect of 90% (95%
CI, 81%–95%).
Results of sensitivity analyses are presented in Table 4.
Whereas estimates of transmission rates varied substantially
across scenarios, the estimated protective effect of early ART re-
mained robust (ranging from 84% to 90%).
Relying on the estimated distribution of coital frequency previ-
ously reported among serodiscordant couples [22], we assumed
a monthly number of 8 episodes of sexual intercourse for those
sexually active in the past month (0 episodes were assumed for
those inactive) and extrapolated the characteristics reported for
the last intercourse to all episodes of intercourse. Based on this
assumption and on our estimate of transmission rates at last
sexual intercourse calculated in the whole studied population, we
estimated that early ART, compared with a standard ART strat-
egy, could prevent 13.4 infections/10 000 patients (95% CI, 9.4–
17.7) during the 12-month period following early ART initiation.
By extrapolating this monthly number to the whole period
(months 0–12), we estimated that early ART could prevent 161
infections/10 000 patients (95% CI, 113–212) in their ﬁrst year of
treatment (based on estimated incidence rate of 18.7 infections/
10 000 persons-years in the early ART group and 179.0 infec-
tions/10 000 person-years in the standard ART group).
Table 1. Baseline Characteristics, by Antiretroviral Therapy
(ART) Strategy
Characteristic
Standard ART,
Patients, No. (%)
(n = 467)
Early ART,
Patients, No. (%)
(n = 490) P
Sex .78
Male 93 (19.9) 94 (19.2)
Female 374 (80.1) 396 (80.8)
Age, y .30
<30 118 (25.3) 118 (24.1)
30–40 217 (46.4) 211 (43.1)
>40 132 (28.3) 161 (32.8)
Education level .10
None 94 (20.1) 131 (26.7)
Primary 144 (30.9) 137 (28.0)
Secondary 170 (36.4) 170 (34.7)
>Secondary 59 (12.6) 52 (10.6)
Personal source of
income
.44
No 116 (26.1) 134 (28.3)
Yes 329 (73.9) 339 (71.7)
Family status .52
Single 200 (42.8) 203 (41.4)
Living in union 218 (46.7) 224 (45.7)
Separated/widowed 49 (10.5) 63 (12.9)
Perceived health .12
Excellent/very
good
100 (21.7) 99 (20.5)
Good 298 (64.6) 295 (60.9)
Poor/bad 63 (13.7) 90 (18.6)
WHO clinical stage .97
1 290 (62.1) 310 (63.3)
2 125 (26.8) 124 (25.3)
3 50 (10.7) 54 (11.0)
4 2 (0.4) 2 (0.4)
CD4+ T-cell count,
cells/mm3
.44
<350 71 (15.2) 88 (17.9)
350–499 176 (37.7) 187 (38.2)
≥500 220 (47.1) 215 (43.9)
Data are from 957 patients who participated in a sociobehavioral study nested
in the Temprano trial and were recorded at the 12-month visit. Patients in the
early arm initiated ART immediately on inclusion in the trial, whereas patients
in the standard arm delayed ART initiation until ongoing WHO starting criteria
were met.
Abbreviation: WHO, World Health Organization.
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DISCUSSION
In this study, which was nested in an ongoing randomized trial
of early ART, patients who initiated ART at high CD4+ T-cell
counts and those who delayed ART initiation until WHO crite-
ria were met declared similar sexual behaviors at 12 months.
Early ART was estimated to decrease the risk of HIV transmis-
sion to partners by 90%. This estimated risk reduction, which
accounted for well-identiﬁed determinants of HIV transmis-
sion, including viral load, sexual partnership, condom use, and
circumcision [19], was mainly attributable to differences in
viral loads between patients receiving early versus standard
ART. In contrast with previous studies that demonstrated the
protective effect of ART among serodiscordant stable couples,
these estimates were derived from a diverse population with a
wide range of partnerships and HIV statuses of partners. More
than half of our patients were not in a cohabiting relationship,
and about two-thirds of those who were sexually active reported
that their last partner was HIV negative or had an unknown
HIV status.
The ﬁrst very original ﬁnding of this study involves sexual
behaviors among patients receiving early ART, which were
comparable to those reported by patients receiving standard
ART 12 months after inclusion. The sample size was large
enough to allow the detection of a 5% difference (from 5% to
10%) between both ART strategies, with a power of 0.95.
Overall proportions of sexual activity in the past year (71%)
and no use of protection during the last episode of intercourse
(25.4%) were consistent with data previously reported in Côte
d’Ivoire for patients treated at late stages of HIV infection [23–
25]. To our knowledge, no data on sexual behaviors in the
context of early ART have been published to date.
According to a recent review conducted in developing coun-
tries, a decrease in unprotected sex was observed in 16 of 17 ob-
servational studies among patients on standard initiated
treatment [11]. Such a decline in unprotected sex associated
with ART may be explained by the multiple medical encoun-
ters that treated patients have with the care system, which
ensures a high level of prevention counseling and psychosocial
support [25, 26]. Routine contact with the healthcare system is
Figure 1. Distribution of plasma human immunodeﬁciency virus type 1 (HIV-1) RNA, by antiretroviral (ART) strategy at baseline (A) and 12 months after
inclusion (B ). A, In the standard ART group, 4.3% had an undetectable viral load at baseline, and the mean viral load among individuals with a detectable
viral load was 4.60 log10 copies/mL (95% conﬁdence interval [CI], 4.52–4.68). In the early ART group, 4.1% had an undetectable viral load at baseline, and
the mean viral load among individuals with a detectable viral load was 4.63 log10 copies/mL (95% CI, 4.55–4.71). B, In the standard ART group, 12.5% had
an undetectable viral load 12 months after inclusion, and the mean viral load among individuals with a detectable viral load was 4.68 log10 copies/mL
(95% CI, 4.60–4.76). In the early ART group, 82.9% had an undetectable viral load 12 months after inclusion, and the mean viral load among individuals with
a detectable viral load was 3.88 log10 copies/mL (95% CI, 3.66–4.11). Patients in the early arm initiated ART immediately on inclusion in the trial, whereas
patients in the standard arm delayed ART initiation until ongoing WHO starting criteria were met. A log10 HIV-1 RNA load of <2.48 log10 copies/mL corresponds
to an HIV-1 RNA detectability threshold of <300 copies/mL.
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often rare for patients who are not eligible for ART [27]. In our
study, participants in the early and standard ART groups had a
high frequency of contact with medical care, which may explain
comparability in self-reported sexual behaviors. Because data
reported in the standard ART initiation context show that
sexual behavior changes may occur over a long period [28],
sexual behavior changes in relation to early ART initiation
deserve to be further assessed over the long term.
We used 3 different indicators to estimate HIV transmission
risk and its reduction. The ﬁrst indicator was the proportion of
last episodes of sexual intercourse exposing the partner to HIV
infection, based on the plasma viral load. This proportion was
signiﬁcantly lower among participants receiving early versus
standard ART. Proportions of unprotected episodes of inter-
course with serodiscordant partners regardless of viral load
were not signiﬁcantly different between both ART strategies.
This suggests that the protective effect of early ART versus a
standard strategy principally lies on the biological effect of the
treatment on viral replication rather than on a combination of
biological and behavioral effect, as suggested by others [11].
Our second estimate of HIV transmission risk was the ex-
pected number of transmissions at the last episode of inter-
course in the past month, combining sexual behavior (condom
use, partner’s HIV status, and circumcision), exact viral loads,
and HIV-1 transmission probabilities from the literature [19].
Table 2. Sexual Behaviors in the Past 12 Months, by Antiretroviral
Therapy (ART) Group
Characteristic
Standard ART,
Patients,
Proportion (%)
Early ART,
Patients,
Proportion (%) P
All patients
Sexually active
in the past year
335/467 (71.7) 342/490 (69.8) .51
Multiple
partnerships
29/467 (6.2) 44/490 (9.0) .11
Patients sexually active in the past year
Last intercourse with a cohabiting partner
Yes 197/335 (58.8) 199/342 (58.2) .87
No 138/335 (41.2) 143/342 (41.8)
Last partner’s HIV status
HIV negative 89/335 (26.6) 78/342 (22.8) .47
HIV positive 99/335 (29.6) 101/342 (29.5)
Unknown 147/335 (43.9) 163/342 (47.7)
Data are from 957 patients who participated in a sociobehavioral study nested
in the Temprano trial and were recorded at the 12-month visit. Patients in the
early arm initiated ART immediately on inclusion in the trial, whereas patients
in the standard arm delayed ART initiation until ongoing WHO starting criteria
were met.
Abbreviation: HIV, human immunodeficiency virus type 1.
Table 3. Characteristics of the Last Episode of Intercourse in the
Past Month, by Antiretroviral Therapy (ART) Group
Characteristic
Standard ART,
Patients, No. (%)
(n = 467)
Early ART,
Patients, No. (%)
(n = 490) P
Last intercourse in the
past month
226 (48.4) 214 (43.7) .14
Unprotected sex at last
intercoursea
100 (21.4) 76 (15.5) .06
Risky sexb at last
intercoursea
60 (12.9) 49 (10.0) .54
Partner’s exposure to
HIVc at last
intercoursea
50 (10.7) 12 (2.45) <10−3
Data are from 957 patients who participated in a sociobehavioral study nested
in the Temprano trial and were recorded at the 12-month visit. Patients in the
early arm initiated ART immediately on inclusion in the trial, whereas patients
in the standard arm delayed ART initiation until ongoing WHO starting criteria
were met.
Abbreviation: HIV, human immunodeficiency virus type 1.
a Last intercourse in the past month.
b Unprotected sex with a partner of HIV-negative/unknown status.
c Unprotected sex with a partner of HIV-negative/unknown status and an HIV
load of >300 copies/mL.
Figure 2. Estimated human immunodeﬁciency virus type 1 (HIV)–trans-
mission rates at the last episode of sexual intercourse in the past month,
by antiretroviral therapy (ART) strategy, per 10 000 sexually active partici-
pants (A; preventive effect, 89% [95% conﬁdence interval {CI}, 79–95])
and per 10 000 participants (B; preventive effect, 90% [95% CI, 81–95]).
Data are from 957 patients who participated in a sociobehavioral study
nested in the Temprano trial and were recorded at the 12-month visit. Pa-
tients in the early arm initiated ART immediately on inclusion in the trial,
whereas patients in the standard arm delayed ART initiation until ongoing
WHO starting criteria were met. Per-act viral load–speciﬁc transmission
probabilities are derived from Hughes et al [19]. Calculations accounted
for sexual activity, condom use, circumcision, and partner’s HIV infection
status.
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This method has been recently used and showed consistent
results as compared to a seroconversion study [29]. On the
basis of this method, we estimated a protective effect of 90% for
early ART. The magnitude of the protective effect we found
was remarkably consistent across populations considered in the
analysis, changes in our assumptions, and variations in the pa-
rameters (Table 4), arguing for the robustness of our estimate.
Moreover, this protective effect was close to those estimated in
the HPTN052 study (96%) [3] and in a systematic review of
prospective studies among discordant couples (91%; 95% CI,
79%–96%) [30].
Third, we assessed the protective effect of early ART by com-
puting the number of infections averted yearly for 10 000
persons after 1 year of treatment, which we estimated between
113 and 212. Those results rely on strong assumptions regard-
ing the frequency of sexual intercourse and the stability over
time of the ART preventive effect in the ﬁrst year of treatment.
Despite the uncertainty surrounding these assumptions, our
results are quite consistent with those from previous studies.
The sensitivity analysis we conducted on the subsample of
stable serodiscordant couples allowed us to estimate HIV inci-
dence rates, which were in the same range than those reported
by the HPTN052 study [3]. Moreover, a previous model esti-
mated that providing early ART (at CD4+ T-cell counts of
350–500 cells/mm3) to serodiscordant couples might be expect-
ed to avert 210 infections per 10 000 person-years of ART [31].
Our estimate of 161 infections averted/10 000 is lower, which is
consistent with the fact that our study included a broader popu-
lation than serodiscordant couples, a substantial portion of
whom (ie, those who are sexually inactive and/or engaged in se-
roconcordant partnerships) do not beneﬁt from the preventive
effect of ART.
Our results were obtained in a population with an early HIV
diagnosis who were engaged in a 30-month trial. The sex ratio
was unbalanced in favor of women, which reﬂects both the
sex-speciﬁc prevalence of HIV infection (6.4% and 2.9%, re-
spectively [20]) and delayed diagnosis among men, who have
lower opportunities for early diagnoses than women in Côte
d’Ivoire [32]. Even if participants of the present study potential-
ly constitute a compliant population engaged in a trial offering
good care conditions, the proportion of viral suppression
achievement in participants receiving early ART 12 months
after enrollment (83%) was not dramatically higher than that
documented in population-based studies throughout sub-
Saharan Africa [33]. This suggests that our results are likely to
be in the range of ﬁgures observed more widely in West Africa.
Our study has some limitations. First, the present behavioral
study was nested in a randomized, controlled clinical trial
whose primary objective was to measure individual rather than
collective beneﬁts and risks of early ART. Thus, before the im-
plementation of the 2012 WHO guidelines [15], our results
were obtained in the absence of speciﬁc information about the
Table 4. Sensitivity Analyses of Estimated Human Immunodeﬁciency Virus type 1 (HIV)–Transmission Rates at the Last Episode of
Intercourse in the Past Month, by Study Arm, and Estimated Protective Effect of the Early Antiretroviral Therapy Strategy
Population
Participants by
Arm, No. Specific Assumption
Expected HIV Transmissions
by Arm, No./10 000
Persons (95% CI)a Protective
Effect, % (95%
CI)Standard Early
Total sample Standard, 467;
early, 490
Main analysis 1.87 (1.39–2.39) 0.20 (.09–.33) 90 (81–95)
Baseline CD4+ T-cell
count >350 cells/
mm3
Standard, 396;
early, 402
Same as in the main analysis 2.03 (1.47–2.66) 0.20 (.08–.36) 90 (81–96)
Cohabiting
serodiscordant
couples
Standard, 55;
early, 54
Same as in the main analysis 3.36 (2.11–4.78) 0.37 (.14–.64) 89 (77–96)
Total sample Standard, 467;
early, 490
viral load = 300 copies/mL for patients
with undetectable viral load
1.88 (1.40–2.40) 0.30 (.19–.43) 84 (75–90)
Total sample Standard, 467;
early, 490
Same as in the main analysis 1.72 (1.36–2.11)b 0.25 (.14–.4)b 85 (75–92)
Total sample Standard, 467;
early, 490
40% of partners with unknown HIV
status considered as HIV-positive
1.34 (1.01–1.70) 0.13 (.07–.22) 90 (82–95)
Total sample Standard, 467;
early, 490
All participants considered as having had
a last unprotected intercourse with a
HIV-negative partner
18.4 (16.6–20.3) 2.1 (1.4–2.9) 89 (84–92)
Data are from 957 patients who participated in a sociobehavioral study nested in the Temprano trial and were recorded at the 12-month visit. Patients in the early
arm initiated ART immediately on inclusion in the trial, whereas patients in the standard arm delayed ART initiation until ongoing WHO starting criteria were met.
a Data are expected no. of transmissions at the last episode of sexual intercourse in the past month. All data are from Hughes et al [19], unless otherwise indicated.
b Data for viral load–specific HIV transmission probabilities are from Gray et al [22].
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preventive effect of ART. The current study may therefore only
partially address the issue of risk compensation. Further re-
search questioning risk perception in the context of widely
available information about the preventive effect of early ART
is needed, both among HIV-infected and HIV-uninfected
people.
Second, the results of this study largely rely on self-reported
sexual behaviors, which are potentially subject to social desir-
ability bias. Overreport of condom use could lead to an under-
estimation of the estimated HIV transmission risks. However,
since counseling and follow-up were similar between both ART
groups, such a bias is unlikely to be differential and, thus, to
have affected our estimate of the preventive effect of early ART.
Third, estimates of HIV transmission risk were based on the
characteristics of the last episode of sexual intercourse. This
might have biased the analysis if the frequency of sexual inter-
course differed between both groups and/or if there were differ-
ences between groups in the extent to which the last episode of
sexual intercourse reﬂected overall sexual behaviors. Such dif-
ferences are unlikely, though, given that both groups were com-
parable for various indicators, including sexual activity and
multiple partnerships.
Fourth, differences between ART strategies in the proportion
of nonresponses to the month 12 questionnaire might have
biased estimations of HIV transmission risk. A lower propor-
tion of participants receiving standard versus early ART com-
pleted the questionnaire during the considered window period
(ie, between months 9 and 15). Patients who completed the
questionnaire outside of this period were mostly individuals
randomly assigned to the standard ART group who initiated
ART during the ﬁrst 12 months of follow-up, which resched-
uled subsequent visits and questionnaire completions from the
date of ART initiation. Compared with other patients receiving
standard ART, patients who started treatment before the 12-
month visit probably had a higher viral load and, therefore,
higher infectiousness during their pre-ART period, followed by
a lower viral load and infectiousness after initiating ART.
When considering the whole period (ie, from months 0–12),
excluding these patients may have led to limited bias in the esti-
mates of the transmission risk among patients receiving stan-
dard ART and of the protective effect of early ART. In addition,
missing the 12-month visit during the window period was
more frequent among patients in the early ART group (38 vs
17). In 2011, because of the political crisis faced by Côte
d’Ivoire, the Temprano staff anticipated violence in Abidjan
and predictable disruption of health services by giving in
advance a higher stock of drugs to patients [34]. Thus, treated
patients might have delayed their 12-month visit without being
necessarily out of treatment.
Expanding ART coverage has resulted in a decreased HIV
infection incidence in South Africa [35], but other natural ex-
periments showed limited effect on HIV transmission,
especially when risk compensation was observed [36]. Commu-
nity trials have started to formally assess the effect of early ART
on HIV infection incidence, but their results will not be re-
leased for several years. Meanwhile, our results suggest a strong
protective effect of early ART on HIV heterosexual transmis-
sion, without any detectable effect on sexual behaviors. This
effect was estimated in a population that included substantial
proportions of persons out of stable partnership or with a sero-
concordant partner. This population was thus more similar to
the whole HIV-infected population than in previous studies, re-
stricted to stable serodiscordant couples. The WHO has recent-
ly recommended early ART initiation for serodiscordant
couples [15]. The social acceptability and equity of prioriti-
zing access to early ART to this population is questionable,
though [37]. Recent modeling studies on the contribution of
HIV transmissions occurring among stable serodiscordant
couples to the global sub-Saharan HIV epidemics demonstrated
that prevention interventions targeted solely those couples may
have a limited public health impact [16, 38]. Our results
provide evidence for the public health signiﬁcance of early
ART initiation among a wider segment of the HIV-infected
population.
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